Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study

American Journal of Cardiovascular Drugs

Volumn 15, Issue 3, 2015, Pages 213-219

  Miyoshi, Toru ^a   Nakamura, Keigo ^b   Doi, Masayuki ^b   Ito, Hiroshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; CREATINE KINASE; EZETIMIBE; HEMOGLOBIN A1C; HETERODIMER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; REMNANT LIKE LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SERINE PROTEINASE; SUBTILISIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; PCSK9 PROTEIN, HUMAN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLOOD EXAMINATION; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPID BLOOD LEVEL; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; MIDDLE AGED;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; EZETIMIBE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PILOT PROJECTS; PROPROTEIN CONVERTASES; PROSPECTIVE STUDIES; SERINE ENDOPEPTIDASES;

EID: 84930273014     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-015-0119-2     Document Type: Article

References (36)

1. Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 2012;11(5):367–83.
2. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–6.
3. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264–72.
4. Kathiresan S. A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction. N Engl J Med. 2008;358(21):2299–300.
5. Lan H, Pang L, Smith MM, Levitan D, Ding W, Liu L, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells. J Cell Physiol. 2010;224(1):273–81.
6. Janis MT, Tarasov K, Ta HX, Suoniemi M, Ekroos K, Hurme R, et al. Beyond LDL-C lowering: distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency. Atherosclerosis. 2013;228(2):380–5.
7. Morris PB, Ballantyne CM, Birtcher KK, Dunn SP, Urbina EM. Review of clinical practice guidelines for the management of LDL-related risk. J Am Coll Cardiol. 2014;64(2):196–206.
8. Yunoki K, Nakamura K, Miyoshi T, Enko K, Kubo M, Murakami M, et al. Impact of hypertriglyceridemia on endothelial dysfunction during statin +/− ezetimibe therapy in patients with coronary heart disease. Am J Cardiol. 2011;108(3):333–9.
9. Nakamura T, Hirano M, Kitta Y, Fujioka D, Saito Y, Kawabata K, et al. A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. J Cardiol. 2012;60(1):12–7.
10. Uemura Y, Watarai M, Ishii H, Koyasu M, Takemoto K, Yoshikawa D, et al. Atorvastatin 10 mg plus ezetimibe 10 mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. J Cardiol. 2012;59(1):50–6.
11. Awan Z, Seidah NG, MacFadyen JG, Benjannet S, Chasman DI, Ridker PM, et al. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem. 2012;58(1):183–9.
12. Tibolla G, Norata GD, Artali R, Meneghetti F, Catapano AL. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition. Nutr Metab Cardiovasc Dis NMCD. 2011;21(11):835–43.
13. Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, Konrad RJ. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res. 2010;51(9):2714–21.
14. Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res. 2008;49(2):394–8.
15. Li S, Jun Li J. PCSK9: a key factor modulating atherosclerosis. J Atheroscler Thromb. 2015;22(3):221–30.
16. Berthold HK, Seidah NG, Benjannet S, Gouni-Berthold I. Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels. PLoS One. 2013;8(3):e60095.
17. Hentze H, Jensen KK, Chia SM, Johns DG, Shaw RJ, Davis HR Jr, et al. Inverse relationship between LDL cholesterol and PCSK9 plasma levels in dyslipidemic cynomolgus monkeys: effects of LDL lowering by ezetimibe in the absence of statins. Atherosclerosis. 2013;231(1):84–90.
18. Berneis K, Rizzo M, Berthold HK, Spinas GA, Krone W, Gouni-Berthold I. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Eur Heart J. 2010;31(13):1633–9.
19. Kubo M, Miyoshi T, Kimura T, Noda Y, Kohno K, Nakamura K, et al. Add-on ezetimibe reduces small dense low-density lipoprotein cholesterol levels without affecting absorption of eicosapentaenoic acid in patients with coronary artery disease: a pilot study. Am J Cardiovasc Drugs Drugs Devices Other Interv. 2014;14(5):387–92.
20. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, et al. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan—2012 version. J Atheroscler Thromb. 2013;20(6):517–23.
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.
22. Schectman G, Patsches M, Sasse EA. Variability in cholesterol measurements: comparison of calculated and direct LDL cholesterol determinations. Clin Chem. 1996;42(5):732–7.
23. Nozue T, Hattori H, Ishihara M, Iwasaki T, Hirano T, Kawashiri MA, et al. Comparison of effects of pitavastatin versus pravastatin on serum proprotein convertase subtilisin/kexin type 9 levels in statin-naive patients with coronary artery disease. Am J Cardiol. 2013;111(10):1415–9.
24. Zhang Y, Liu J, Li S, Xu RX, Sun J, Li JJ. Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats. Lipids Health Dis. 2014;13:35.
25. Huijgen R, Boekholdt SM, Arsenault BJ, Bao W, Davaine JM, Tabet F, et al. Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study. J Am Coll Cardiol. 2012;59(20):1778–84.
26. Lakoski SG, Xu F, Vega GL, Grundy SM, Chandalia M, Lam C, et al. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J Clin Endocrinol Metab. 2010;95(2):800–9.
27. Han L, Li M, Liu Y, Han C, Ye P. Atorvastatin may delay cardiac aging by upregulating peroxisome proliferator-activated receptors in rats. Pharmacology. 2012;89(1–2):74–82.
28. Sanderson LM, Boekschoten MV, Desvergne B, Muller M, Kersten S. Transcriptional profiling reveals divergent roles of PPARalpha and PPARbeta/delta in regulation of gene expression in mouse liver. Physiol Genomics. 2010;41(1):42–52.
29. Alagona P Jr. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. Am J Manag Care. 2009;15(3 Suppl):S65–73.
30. Nakamura T, Obata JE, Hirano M, Kitta Y, Fujioka D, Saito Y, et al. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals. Atherosclerosis. 2011;218(1):163–7.
31. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990;82(2):495–506.
32. Christopher P Cannon on behalf of the IMPROVE IT Investigators. IMPROVE-IT Trial: a comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation. 2014;130:2105–26 doi:10.1161/01.cir.0000457464.79076.2c.
33. Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol. 2014;11(10):563–75.
34. Stein EA, Swergold GD. Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics. Curr Atheroscler Rep. 2013;15(3):310.
35. Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870–82.
36. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015. doi:10.1056/NEJMoa1500858.